in 2018 as the first treatment for hemophagocytic lymphohistiocytosis. In July 2019, Novimmune divested Gamifant and related activities, and rebranded as Light Chain Bioscience with a focus on ...

In 2018, Sobi acquired the global rights to emapalumab, the first and only treatment for primary hemophagocytic lymphohistiocytosis (HLH), recently approved for the treatment of primary HLH in the US.

LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in ...

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced that the U.S. Food and ...

I just look back and say, 'Thank God I made it through.' As a toddler in Cincinnati, Ohio, William was diagnosed with hemophagocytic lymphohistiocytosis, a rare, life-threatening disorder in which the ...

In the US, emapalumab-lzsg is indicated for pediatric (newborn and older) and adult primary hemophagocytic lymphohistiocytosis (HLH) patients with refractory, recurrent or progressive disease, or ...

IEC-HS includes the preferred terms IEC-HS, HLH, Hemophagocytic lymphohistiocytosis, and atypical HLH. Two patients developed an inflammatory syndrome prior to the existence of IEC-HS as a term in ...

Ding, B. , Wu, Y. , Zhang, Y. and Li, Y. (2024) CXCL10 Induces Lytic Reactivation of EBV through EXTL 1. Advances in ...

ILT: Immunoglobulin-like transcript; KIR: Killer cell immunoglobulin-like receptor; LIR: Leukocyte immunoglobulin-like receptor; MIC: MHC class I-like; NKR: Natural killer cell receptor; ULBP ...